Clinical Research Directory
Browse clinical research sites, groups, and studies.
Protective Effect of Ulinastatin and Thymosin α1 Against Negative Immune Dysregulation and Organ Dysfunction After Acute Aortic Dissection Surgery (PANDA XI)
Sponsor: Nanjing Medical University
Summary
Systemic inflammatory response syndrome (SIRS) and multiple organ dysfunction syndrome (MODS) are the major causes of death in patients with acute aortic syndrome (AAS). Therefore, the prevention of SIRS and MODS is of great clinical value, and immunomodulatory therapy with thymosin alpha 1 in addition to antiinflammatory treatment may be beneficial. This study was designed to test the hypothesis that the administration of Ulinastatin and Thymosin α1 during the acute phase of AAS will result in a reduced incidence of SIRS and MODS.
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
200
Start Date
2025-04-01
Completion Date
2026-12-31
Last Updated
2026-01-14
Healthy Volunteers
No
Interventions
Ulinastatin and Thymosin α1
Ulinastatin (100000U TID for 5 days) and Thymosin alpha 1 (1.6 mg q12h for 5 days) immediately after surgery
Ulinastatin only
Ulinastatin (100000U TID for 5 days) immediately after surgery
Locations (4)
Beijing Anzhen Hospital
Beijing, Beijing Municipality, China
The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China
Shanghai East Hospital Tongji University
Shanghai, Shanghai Municipality, China
West China Hospital
Chengdu, Sichuan, China